| Literature DB >> 33935511 |
Li Zhang1, Xiaoping Li1, Jiang Lu1, Yi Qian1, Tao Qian1, Xing Wu1, Qinghua Xu1.
Abstract
BACKGROUND: Previous studies have shown that epidermal growth factor receptor (EGFR) promotes cell proliferation through the PI3K-Akt-mTOR signaling pathway and participates in the occurrence and development of hepatocellular carcinoma (HCC). Here, we focused on the functional polymorphism of EGFR in the 3'-untranslated region (UTR), aiming to reveal the potential mechanisms by which functional polymorphism is associated with the risk and development of HCC in the Han Chinese population.Entities:
Keywords: EGFR; HCC; epidermal growth factor receptor; hepatocellular carcinoma; miR-3196; polymorphism; proliferation
Year: 2021 PMID: 33935511 PMCID: PMC8079348 DOI: 10.2147/PGPM.S304524
Source DB: PubMed Journal: Pharmgenomics Pers Med ISSN: 1178-7066
Clinical Characteristics of HCC Patients and Cancer-Free Controls
| Variables | Cases (n = 600) | Controls (n = 600) | |||
|---|---|---|---|---|---|
| N | % | N | % | ||
| ≤ 60 | 350 | 58.3 | 330 | 55.0 | 0.244 |
| > 60 | 250 | 41.7 | 270 | 45.0 | |
| Male | 481 | 80.2 | 482 | 80.3 | 0.942 |
| Female | 119 | 19.8 | 118 | 19.7 | |
| HBV/HCV | 477 | 79.5 | 35 | 5.8 | <0.0001 |
| Negative | 123 | 20.5 | 565 | 94.2 | |
| Positive | 301 | 50.2 | 289 | 48.2 | 0.488 |
| Negative | 299 | 49.8 | 311 | 51.8 | |
| Positive | 302 | 50.3 | 291 | 48.5 | 0.525 |
| Negative | 298 | 49.7 | 309 | 51.5 | |
| Positive | 311 | 51.8 | 299 | 49.8 | 0.488 |
| Negative | 289 | 48.2 | 301 | 50.2 | |
| Positive | 219 | 36.5 | 203 | 33.8 | 0.333 |
| Negative | 381 | 63.5 | 397 | 66.2 | |
Notes: *Two-sided chi-square test for analyzing the clinical characteristics of HCC patients and cancer-free controls.
The Genotype Distribution of the SNP rs884225 in HCC Patients and Cancer–Free Controls
| Genotype | Cases (n =600) | Controls (n = 600) | OR (95% CI)a | |||
|---|---|---|---|---|---|---|
| N | % | N | % | |||
| TT | 565 | 94.2 | 479 | 79.8 | 1.00 | |
| TG | 21 | 3.5 | 71 | 11.8 | 0.45 (0.21–0.66) | |
| GG | 14 | 2.3 | 50 | 8.4 | 0.38 (0.33–0.58) | |
| G carrier | 35 | 5.8 | 121 | 20.2 | 0.41 (0.25–0.61) | |
Notes: aThe ORs, 95% CIs and P value were calculated after adjusting for age, gender. Significant p value was labelled in bold.
The Stratified Analysis of Association Between rs884225 and HCC Risk
| Feather | Genotype | TG vs TT | GG vs TT | ||
|---|---|---|---|---|---|
| TT | TG | GG | |||
| Well | 301 | 11 | 6 | 0.782 | 0.726 |
| Moderate | 156 | 7 | 5 | ||
| Poorly | 108 | 3 | 3 | ||
| Solitary | 344 | 15 | 9 | 0.330 | 0.797 |
| Multiple | 221 | 6 | 5 | ||
| ≤5cm | 168 | 17 | 13 | ||
| >5cm | 397 | 4 | 1 | ||
| Incomplete | 182 | 7 | 5 | 0.914 | 0.782 |
| Complete | 383 | 14 | 9 | ||
| Yes | 188 | 7 | 4 | 0.996 | 0.712 |
| No | 377 | 14 | 10 | ||
Notes: *Two-sided chi-square test for either genotype distributions or allele frequencies between cases and controls. Significant p value was labelled in bold.
Figure 1EGFR rs884225 SNP could bind with miR-3196 causing the suppression of EGFR and cell proliferation. (A) Expression of EGFR in HCC patients with TT, TG or GG genotype. (B) The CCK8 assay in HepG2 cell line treated with EGFR with different genotypes under miR-3196 stimulation. (C) Schematic diagram of specific binding sites of miRNA-3196 and EGFR. (D) Expression of miR-3196 in HCC patients with TT, TG or GG genotype. (E) Dual luciferase reporter gene assay in HepG2 and MHCC-97H cell lines. The data were presented as the mean ± SD. **Indicates P<0.01. *Indicates P<0.05. (left panel) HepG2 cell line, (right panel) MHCC-97H cell line.
Figure 2EGFR rs884225 SNP reduced the cell proliferation through the miR-3196-dependent approach. (A) CCK8 assay was detected in HCC cells treated with different expression of miR-3196 with EGFR mutant type or wild type. (B) The expression of Ki67, phosphorylation of ERK and AKT in HCC cells. *Indicates P<0.05.